Literature DB >> 2122435

Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme.

H Bundgaard1, J Møss.   

Abstract

Bioreversible derivatization of TRH (pGlu-His-Pro-NH2) to protect the tripeptide against rapid enzymatic inactivation in the systemic circulation and to improve the lipophilicity of this highly hydrophilic peptide was performed by N-acylation of the imidazole group of the histidine residue with various chloroformates. Whereas TRH was rapidly hydrolyzed at its pGlu-His bond in human plasma by a TRH-specific pyroglutamyl aminopeptidase serum enzyme, the N-alkoxycarbonyl derivatives were resistant to cleavage by the enzyme. On the other hand, these derivatives are readily bioreversible as the parent TRH is formed quantitatively from the derivatives by spontaneous hydrolysis or by plasma esterase-catalyzed hydrolysis. In addition to protecting the parent TRH against rapid inactivation in the circulation and hence potentially prolonging the duration of action of TRH in vivo, the N-alkoxycarbonyl prodrug derivatives were much more lipophilic than TRH as assessed by octanol-buffer partitioning. This property may enhance prodrug penetration of the blood-brain barrier and various other biomembranes compared to the parent peptide.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122435     DOI: 10.1023/a:1015933504191

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  33 in total

1.  Characterization of a thyroliberin-degrading serum enzyme catalyzing the hydrolysis of thyroliberin at the pyroglutamyl-histidine bond.

Authors:  K Bauer; P Nowak
Journal:  Eur J Biochem       Date:  1979-09

2.  Imidazole catalysis. II. Acyl transfer and the reactions of acetyl imidazole with water and oxygen anions.

Authors:  W P JENCKS; J CARRIUOLO
Journal:  J Biol Chem       Date:  1959-05       Impact factor: 5.157

3.  Characterization of a pyroglutamate aminopeptidase from rat serum that degrades thyrotropin-releasing hormone.

Authors:  W L Taylor; J E Dixon
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

4.  Kinetics and pattern of degradation of thyrotropin-releasing hormone (TRH) in human plasma.

Authors:  J Møss; H Bundgaard
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

5.  Ethoxyformylation of proteins. Reaction of ethoxyformic anhydride with alpha-chymotrypsin, pepsin, and pancreatic ribonuclease at pH 4.

Authors:  W B Melchior; D Fahrney
Journal:  Biochemistry       Date:  1970-01-20       Impact factor: 3.162

6.  A comparison of thyrotropin-releasing hormone with analogs: influence of disposition upon pharmacology.

Authors:  M Hichens
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

7.  Orientation restrictions of the peptide hormone, thyrotropin-releasing factor, due to intramolecular hydrogen bonding.

Authors:  G Grant; N Ling; J Rivier; W Vale
Journal:  Biochemistry       Date:  1972-08-01       Impact factor: 3.162

8.  [Pharmacokinetics and pharmacodynamics of protirelin (TRH) in man].

Authors:  L Duntas; F S Keck; U Loos; E F Pfeiffer
Journal:  Dtsch Med Wochenschr       Date:  1988-09-02       Impact factor: 0.628

Review 9.  Regulatory peptides as a source of new drugs--the clinical prospects for analogues of TRH which are resistant to metabolic degradation.

Authors:  G Metcalf
Journal:  Brain Res       Date:  1982-11       Impact factor: 3.252

10.  Pilocarpine prodrugs. II. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters.

Authors:  H Bundgaard; E Falch; C Larsen; G L Mosher; T J Mikkelson
Journal:  J Pharm Sci       Date:  1986-08       Impact factor: 3.534

View more
  8 in total

Review 1.  CNS drug delivery: opioid peptides and the blood-brain barrier.

Authors:  Ken A Witt; Thomas P Davis
Journal:  AAPS J       Date:  2006-02-24       Impact factor: 4.009

Review 2.  Enhancing the buccal mucosal delivery of peptide and protein therapeutics.

Authors:  Thiago Caon; Liang Jin; Cláudia M O Simões; Raymond S Norton; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-08-29       Impact factor: 4.200

3.  Prodrugs of peptides. 9. Bioreversible N-alpha-hydroxyalkylation of the peptide bond to effect protection against carboxypeptidase or other proteolytic enzymes.

Authors:  H Bundgaard; G J Rasmussen
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

4.  Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity.

Authors:  J Wang; D Shen; W C Shen
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

5.  Development of new lipophilic derivatives of tetragastrin: physicochemical characteristics and intestinal absorption of acyl-tetragastrin derivatives in rats.

Authors:  T Tenma; E Yodoya; S Tashima; T Fujita; M Murakami; A Yamamoto; S Muranishi
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

6.  Prodrugs of peptides. 13. Stabilization of peptide amides against alpha-chymotrypsin by the prodrug approach.

Authors:  A H Kahns; H Bundgaard
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

7.  Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates.

Authors:  Jeff Wang; Daphne Wu; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

Review 8.  The Thyrotropin-Releasing Hormone-Degrading Ectoenzyme, a Therapeutic Target?

Authors:  Jean-Louis Charli; Adair Rodríguez-Rodríguez; Karina Hernández-Ortega; Antonieta Cote-Vélez; Rosa María Uribe; Lorraine Jaimes-Hoy; Patricia Joseph-Bravo
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.